The Korean Ministry of Health and Welfare’s “Infectious Disease Prevention and Treatment Technology Development Project” has selected Microbiotix to conduct the first Korean phage clinical trial. This clinical trial has found its funding support from MicrobiotX.
Microbiotix, Inc. is a clinical-stage biopharmaceutical company whose main focus is the discovery and development of proprietary small-molecule drugs that target serious infectious diseases, including multidrug-resistant pathogens. Microbiotix is also developing novel phage-based therapeutics.
As part of the investment, Microbiotix has now completed an extended Series B investment of over 20 billion KRW(South Korean Won) in 2025. This collaborative effort and funding between the Korean Government and Microbiotix will contribute to more clinical trials and subsequent commercialization of phage therapies globally.
Dongeun Yong, the CEO of MicrobiotiX, said in a statement that, “Through conducting the first clinical trial of its kind in Korea, we are responding to the global health crisis presented by antibiotic-resistant bacterial infections.”
Read the full news here.
